Alexion Pharmaceuticals, Inc.

Alexion Pharmaceutiacls, Inc.

Yale University

Yi Wang

Paul P Tamburini

Bruce A Andrien, Jr

Douglas L Sheridan

Louis A Matis

Xiao-Hong Zhou

John P Mueller

Scott A Rollins

Susan Faas McKnight

Jordan S Pober

Hao Wang

Zhao Xue Yu

Barbel Rohrer

Lingfeng Qin

Daniel Jane-Wit

Bruce A Andrien

The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.

Anti-C5 antibodies having improved pharmacokinetics

The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.

Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody

The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.

Compositions comprising an anti-C5 antibody

Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies

Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies

The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Also featured are therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.

Kits comprising formulations of anti-C5 antibodies

Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodies

The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti-CD200 antibody has produced a desired immunomodulatory effect in a mammal. Also featured are pharmaceutical compositions, kits, and solutions that contain at least one anti-CD200 antibody and are useful in the methods described herein.

Use of an anti-CD200 antibody for prolonging the survival of allografts

High concentration formulations of anti-C5 antibodies

Methods for treating patients with complement-associated disorders with high concentration formulations of anti-C5 antibodies

High concentration antibody formulations

Growing community of inventors

Woodbridge, CT, United States of America

Yi Wang